Issues
-
Cover Image
Cover Image
Defective mismatch repair (MMR) in humans causes hereditary nonpolyposis colorectal cancer. This genetic predisposition to colon cancer is linked to heterozygous familial mutations, and loss-of-heterozygosity is necessary for tumor development. Existing mouse knockout models show only partial overlap in the tumor spectrum. Novel zebrafish knockout mutants for the MMR genes msh6, msh2 and mlh1 were generated by target-selected mutagenesis. These fish were found to display microsatellite instability and to develop tumors. Although the tumor spectrum is different from the mouse, it does partially resemble the spectrum of rare patient cases with biallelic MMR mutations. MMR-deficient fish develop predominantly neurofibromas/malignant peripheral nerve sheath tumors, but several other tumor types were also found. The image shows high (first row) and medium (second row) magnifications of histological cross sections (third row) as well as macroscopical images (fourth row) of an ocular neurofibroma (first column), an olfactory neuroblastoma (second column), a primitive neuroectodermal tumor in the brain (third column), and a hemangiosarcoma (fourth column) that were identified in msh6-/- and mlh1-/- fish. Our work shows that the zebrafish is a useful cancer model that provides new insights and experimental possibilities, and complements studies in mouse models and humans. For details, see the article by Feitsma et al. on page 5059 of this issue. - PDF Icon PDF LinkTable of Contents
Cancer Research
Table of Contents
Reviews
Meeting Report
Priority Reports
Identification of Novel Isoforms of the EML4-ALK Transforming Gene in Non–Small Cell Lung Cancer
Transporter-Mediated Protection against Thiopurine-Induced Hematopoietic Toxicity
Complement-Dependent Tumor Cell Lysis Triggered by Combinations of Epidermal Growth Factor Receptor Antibodies
Molecular Biology, Pathobiology, and Genetics
15-Hydroxyprostaglandin Dehydrogenase is a Target of Hepatocyte Nuclear Factor 3β and a Tumor Suppressor in Lung Cancer
Cell, Tumor, and Stem Cell Biology
Genomic and Proteomic Analysis Reveals a Threshold Level of MYC Required for Tumor Maintenance
NO Signaling Confers Cytoprotectivity through the Survivin Network in Ovarian Carcinomas
Tumor Microenvironment
Experimental Therapeutics, Molecular Targets, and Chemical Biology
Aplidin, a Marine Organism–Derived Compound with Potent Antimyeloma Activity In vitro and In vivo
Cross-talk between Notch and the Estrogen Receptor in Breast Cancer Suggests Novel Therapeutic Approaches
Improved Cellular Pharmacokinetics and Pharmacodynamics Underlie the Wide Anticancer Activity of Sagopilone
Increasing Melanoma Cell Death Using Inhibitors of Protein Disulfide Isomerases to Abrogate Survival Responses to Endoplasmic Reticulum Stress
Systems Biology and Emerging Technologies
Immunology
Endocrinology
Clinical Research
Prevention
Journal Archive
Cancer Research
(1941-Present; volumes 1-current)Published twice monthly since 1987. From 1941-1986, published monthly.
(ISSN 0008-5472)
The American Journal of Cancer
(1931-1940; volumes 15-40)Published quarterly in 1931, bimonthly in 1932, and monthly from 1933 to 1940. The journal changed title to Cancer Research in 1941.
(ISSN 0099-7374)
The Journal of Cancer Research
(1916-1930); volumes 1-14)Published quarterly from 1916 through 1930 (publication was suspended from November 1922 to March 1924). The journal changed title to The American Journal of Cancer in 1931.
(ISSN 0099-7013)
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.